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Abstract
Hepatitis C virus (HCV) infection is closely tied to the lipid metabolism of liver cells. Here, we 
identify the triglyceride-synthesizing enzyme DGAT1 as an important host factor for HCV 
infection; DGAT1 interacts with the viral nucleocapsid core and is required for the trafficking of 
core to lipid droplets. Inhibition of DGAT1 activity or RNAi-mediated knockdown severely 
impairs infectious virion production, implicating DGAT1 as a new target for antiviral therapy.
Over 160 million individuals are infected with HCV, and in ~80% of cases, infection 
persists and can lead to severe liver disease. No vaccine is available, and current treatments 
are not effective against the strains most prevalent in the US and Europe. After the virus 
enters liver cells, a viral polyprotein is translated at the endoplasmic reticulum (ER) from a 
single positive-stranded RNA genome and processed into structural and nonstructural 
proteins1. Nonstructural proteins autonomously replicate viral RNA, which together with 
structural proteins, the nucleocapsid core and E1 and E2 envelope proteins, is packaged into 
progeny virions. Both RNA replication and infectious particle assembly are thought to occur 
at ER membranes. However, recent reports showed a critical involvement of lipid droplets 
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(LDs) in infectious virion production2–4, and viral budding requires the lipoprotein secretion 
pathway5–7.
LDs form when triglycerides and cholesterol esters accumulate between the bilayer of the 
ER membrane and are surrounded by a phospholipid monolayer and associated proteins8. 
DGAT1 and DGAT2 enzymes catalyze the final step in triglyceride biosynthesis and are 
critical in LD biogenesis9. Both enzymes are ER-resident, and upon uptake of fatty acids, 
DGAT2, but not DGAT1, localizes to LDs9. Both enzymes have similar activities in vitro; 
however, DGAT1 has broader substrate specificity9, and only DGAT2 is essential in vivo in 
vivo10,11.
To determine if DGAT enzymes influence the HCV life cycle, shRNAs directed against 
DGAT1 or DGAT2 were introduced into HCV-permissive hepatoma cells12–14. Transduced 
cultures were inoculated with low concentrations of infectious HCV expressing eGFP as a 
marker for infection (eGFP-Jc1), and viral spread was monitored by flow cytometry (Fig. 
1a). Spreading infection was suppressed by 65–90% with two DGAT1 shRNAs (day 9 post 
infection). Expression of shRNA-resistant DGAT1 rescued the suppressive effect of the 
DGAT1 knockdown on viral infection (Supplementary Fig. S1). No change was seen with 
DGAT2 shRNA pointing to a unique role of DGAT1 in HCV infection. Knockdown of 
DGAT expression was verified by real-time RT-PCR and, for DGAT1, by western blotting 
(Fig. 1b).
Similar results were obtained in infected hepatoma cells treated with a DGAT1-specific 
small molecule inhibitor (further described in Supplementary Fig. S2). Increasing 
concentrations of DGAT1 inhibitor caused a gradual decline in infectious viral particle 
production for infectious HCV-Jc1 and HCV-JFH1 expressing firefly luciferase as infection 
marker (Fig. 1c; IC50 Luc-Jc1 = 7.3 μM; Luc-JFH1 = 7.4 μM). Experiments with the 
DGAT1 inhibitor were also performed in freshly isolated primary human hepatocytes15. 
Cells were inoculated with infectious HCV-Jc1
,
 and focus-forming units were measured 
after transfer of infectious supernatant from primary cells to permissive hepatoma cells. 
Primary hepatocytes were effectively infected and produced viral titers similar to hepatoma 
cells (Supplementary Fig. S3a). Production of infectious viral particles was suppressed by 
DGAT1 inhibitor treatment, albeit at higher concentrations than in hepatoma cells (Fig. 1d). 
These data show that DGAT1 activity is necessary for efficient propagation of HCV in 
transformed and primary human liver cells.
To identify which step in the HCV life cycle requires DGAT1, we quantified intracellular 
and secreted HCV RNA in infected hepatoma cells. Treatment with the DGAT1 inhibitor 
reduced viral RNA released into the culture supernatant by ~80%, while intracellular viral 
RNA concentrations remained unchanged (Fig. 1e, Supplementary Fig. S3c). No change in 
intracellular viral protein expression was observed (Fig. 1f). Thus, DGAT1 activity is not 
required for viral RNA replication and translation, but likely controls HCV infection at the 
level of virion assembly or release.
To differentiate between these possibilities, viral particles were isolated from infected cells 
and used to inoculate naïve cells. Intracellular infectivity was decreased in DGAT1 
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inhibitor-treated cultures, indicating that viral assembly is the step in the viral life cycle 
mainly regulated by DGAT1, although additional effects on viral release cannot be excluded 
(Fig. 1g).
Because LDs are critically involved in HCV assembly, we speculated that loss of DGAT1 
activity reduced cellular LD levels and thus caused the reduction in infectious particle 
production. Unexpectedly, no change in overall neutral lipid content, LD size, or LD 
numbers was observed in DGAT1 inhibitor-treated hepatoma cells (Fig. 1h). Indeed, levels 
of triglycerides, cholesterol esters, phospholipids, and secreted lipoproteins remained 
unchanged in cells treated with the DGAT1 inhibitor or shRNAs against DGAT1 or 
DGAT2, while knockdown of both DGAT enzymes together efficiently reduced neutral 
lipid content and LD numbers (Supplementary Fig. S4). These results show that the two 
DGAT enzymes have redundant functions in lipid synthesis in hepatoma cells and that a 
more complex mechanism than the mere reduction of LDs is responsible for the inhibitory 
effect on HCV infection.
We focused our efforts on the viral core protein because it localizes to LDs, and this 
localization plays a critical role in HCV particle assembly2,4,16. Core represents the first 191 
amino acids of the viral polyprotein and anchors the polyprotein at the ER membrane with 
its C-terminal signal peptide17. After two sequential C-terminal cleavages, processed core 
remains attached to the cytoplasmic leaflet of the ER membrane and from there gains access 
to the surface of LDs18.
To determine if DGAT1 regulates core association with LDs, LD fractions were isolated 
from infected cells. Core was present in the LD fraction isolated from control-treated, but 
not DGAT1 inhibitor-treated cells, demonstrating that core association with LDs depends on 
DGAT1 (Fig. 1i). Similar results were obtained with the viral NS3 protein, which together 
with core localizes to LDs during active HCV particle production (Fig. 1i),2,19. LD fractions 
contained similar amounts of the LD-resident adipose differentiation-related protein 
(ADRP), while ER-resident proteins calreticulin and GRP78/BiP were absent.
Immunofluorescence microscopy confirmed that the core protein was retained at the ER in 
hepatoma cells treated with the DGAT1 inhibitor or expressing shRNAs against DGAT1, 
but not DGAT2 (Supplementary Fig. S5a,c). In contrast, overexpression of DGAT1 in HeLa 
cells, which harbor very few LDs, was sufficient to localize core from the ER to LDs, a 
process reversible by the addition of the DGAT1 inhibitor (Supplementary Fig. S6).
Since the localization of core to LDs is critical to recruit viral RNA replication complexes to 
the close proximity of LDs2, we stained HCV-infected cells with antibodies detecting viral 
double-stranded (ds) RNA20. While in vehicle-treated cells, a subset of LDs was decorated 
with signals for dsRNAs, very little overlap between LD- and dsRNA-generated signals was 
seen in DGAT1 inhibitor-treated cells (Fig. 1j). These results support the model that 
packaging of viral genomes into progeny virions requires DGAT1.
To study the molecular mechanism how DGAT1 regulates core trafficking to LDs, we 
performed coimmunoprecipitation experiments. Core associated with Flag-Dgat1, but not 
Flag-Dgat1, after coexpression in 293T cells; the interaction was not interrupted by the 
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DGAT1 inhibitor (Fig. 2a). In addition, core efficiently coimmunoprecipitated with 
catalytically inactive Dgat1 (H426A), excluding that the interaction requires the enzymatic 
activity of DGAT1 (Supplementary Fig. S7). Core also coimmunoprecipitated with 
endogenous DGAT1 after lentiviral expression in hepatoma cells (Fig. 2b) and in two 
permissive hepatoma cell lines infected with HCV-Jc1 (Fig. 2c). However, despite the 
protein-protein interaction, no marked colocalization of both proteins was observed in 
immunofluorescence microscopy. Endogenous DGAT1 showed a reticular localization 
while the core protein mainly localized to punctate structures corresponding to LDs (Fig. 
2d). After core expression, DGAT1 appeared more concentrated around LDs carrying core, 
but no significant overlap was observed. Notably, treatment with DGAT1 inhibitor or 
knockdown of DGAT2 did not affect the subcellular localization of DGAT1 (Supplementary 
Fig. S5b,d).
We speculated that core only transiently interacts with DGAT1 when produced at the ER 
before migrating to LDs and examined a core mutant (SPMT) that cannot access LDs18. The 
SPMT mutant colocalized with endogenous DGAT1 in support of the model that both 
proteins interact at the ER (Fig. 2d). In agreement with this model, Flag-Dgat1 interacted 
stronger with the ER-retained SPMT mutant than with wild-type core in 
coimmunoprecipitation experiments (Fig. 2e). A truncated core mutant lacking the C-
terminal signal peptide (core 1–173) coimmunoprecipitated with Dgat1, showing that this 
region does not mediate the interaction.
Collectively, our observations identify a hitherto unrecognized function of DGAT1 as a host 
factor for HCV infection. They demonstrate that infectious HCV particle production does 
not randomly occur in the vicinity of LDs but requires DGAT1-mediated LD formation. 
DGAT1 binds the HCV core protein and localizes core to DGAT1-generated LDs, thereby 
recruiting viral RNA replication complexes to the proper site of viral assembly (Fig. 2f). In 
cells treated with the DGAT1 inhibitor, core still interacts with DGAT1 but cannot access 
LDs as DGAT1-generated LDs no longer form. As a consequence, production of infectious 
viral particles is impaired despite the presence of LDs generated by DGAT2.
Why HCV selectively targets DGAT1, and not DGAT2, remains unknown at this point. 
However, the finding that DGAT2-generated LDs form normally in DGAT1 inhibitor-
treated cells points to a unique opportunity for therapeutic intervention. DGAT1 inhibitors, 
currently in early clinical trials for obesity-associated diseases, may serve as novel antiviral 
therapeutics that selectively suppress HCV’s interaction with LDs without compromising 
the overall formation of lipid droplets in liver cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Eric Yen for Sf9 cell lysates, Ralf Bartenschlager, Charles M. Rice, Francis V. Chisari, John 
McLauchlan, and Takaji Wakita for cell lines, infectious HCV constructs and helpful discussions, Matt Spindler for 
the pSicoRMS, and members of the Ott and Farese laboratories for support. This work was supported by funds from 
the Gladstone Institutes, the Hellman Family Foundation (M.O.) and the NIH (R03 AI069090 (M.O.); R01 
Herker et al. Page 4









DK056084 (R.F.); P30 DK026743 (UCSF Liver Center). We gratefully acknowledge support through fellowships 
from the Human Frontiers Science Program (E.H.), the INRS (Ce.H. and A.C.), and a Training Grant from NIDDK 
(Ch.H.).
References
1. Moradpour D, Penin F, Rice CM. Nat Rev Microbiol. 2007; 5:453–463. [PubMed: 17487147] 
2. Miyanari Y, et al. Nat Cell Biol. 2007; 9:1089–1097. [PubMed: 17721513] 
3. Roingeard P, Hourioux C, Blanchard E, Prensier G. Histochem Cell Biol. 2008; 130:561–566. 
[PubMed: 18512067] 
4. Boulant S, Targett-Adams P, McLauchlan J. J Gen Virol. 2007; 88:2204–2213. [PubMed: 
17622624] 
5. Huang H, et al. Proc Natl Acad Sci USA. 2007; 104:5848–5853. [PubMed: 17376867] 
6. Chang KS, Jiang J, Cai Z, Luo G. J Virol. 2007; 81:13783–13793. [PubMed: 17913825] 
7. Gastaminza P, et al. J Virol. 2008; 82:2120–2129. [PubMed: 18077707] 
8. Farese RV Jr, Walther TC. Cell. 2009; 139:855–860. [PubMed: 19945371] 
9. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. J Lipid Res. 2008; 49:2283–2301. [PubMed: 
18757836] 
10. Smith SJ, et al. Nat Genet. 2000; 25:87–90. [PubMed: 10802663] 
11. Stone SJ, et al. J Biol Chem. 2004; 279:11767–11776. [PubMed: 14668353] 
12. Wakita T, et al. Nat Med. 2005; 11:791–796. [PubMed: 15951748] 
13. Lindenbach BD, et al. Science. 2005; 309:623–626. [PubMed: 15947137] 
14. Zhong J, et al. Proc Natl Acad Sci USA. 2005; 102:9294–9299. [PubMed: 15939869] 
15. Podevin P, et al. Gastroenterology. 201010.1053/j.gastro.2010.06.058
16. Barba G, et al. Proc Natl Acad Sci USA. 1997; 94:1200–1205. [PubMed: 9037030] 
17. Selby MJ, et al. J Gen Virol. 1993; 74(Pt 6):1103–1113. [PubMed: 8389800] 
18. McLauchlan J, Lemberg MK, Hope G, Martoglio B. EMBO J. 2002; 21:3980–3988. [PubMed: 
12145199] 
19. Ma Y, Yates J, Liang Y, Lemon SM, Yi M. J Virol. 2008; 82:7624–7639. [PubMed: 18508894] 
20. Targett-Adams P, Boulant S, McLauchlan J. J Virol. 2008; 82:2182–2195. [PubMed: 18094154] 
Herker et al. Page 5









Fig. 1. DGAT1 activity is necessary for HCV particle assembly at LDs
(a) Infection of shRNA-expressing Huh7.5 cells with low concentrations of eGFP-Jc1 viral 
stock. Spreading viral infection was measured by flow cytometry of eGFP (mean ± s.e.m.; n 
= 4; *p < 0.05, **p < 0.01). (b) Real-time RT-PCR analysis of DGAT1 or DGAT2 mRNAs 
in knockdown cells (mean ± s.e.m.; n = 4) or western blot analysis of DGAT1 protein 
expression. Available antibodies against DGAT2 do not reliably detect endogenous human 
DGAT2 in our hands. (c) Dose-dependent decrease of infectious titres in Huh7.5 cells 
transfected with Luciferase-Jc1 or Luciferase-JFH1 RNA and incubated with increasing 
concentrations of the DGAT1 inhibitor or DMSO for 48 h. Naïve Huh7.5 cells were infected 
with cell supernatants of treated cells and lysed 48 h post-infection to analyze luciferase 
activity (expressed as percent relative to DMSO control; mean ± s.e.m.: n = 3). (d) Dose-
dependent decrease of infectious virus titers released from freshly isolated primary human 
hepatocytes infected with HCV-Jc1 viral stock and treated with increasing amounts of the 
DGAT1 inhibitor or DMSO for 3 days. Shown are infectivity titers (in FFU) expressed as 
percent of DMSO control. A single experiment is shown. (e) Real-time RT-PCR analysis of 
HCV RNA isolated from cells or from supernatants of Huh7.5 cells electroporated with 
eGFP-Jc1 RNA and treated with DGAT1 inhibitor (20 μM) or DMSO. Results are expressed 
as HCV RNA copy numbers per 1 μg total cellular RNA normalized to 18S rRNA 
(Intracellular) or per 1 ml culture supernatant (Secreted) at day 4 after transfection (mean ± 
s.d.; n = 6; **p < 0.01). (f) Western blot analysis of cell extracts described in e) lysed at day 
4 after transfection. (g) Infection of naïve Huh7.5 cells with either intracellular or secreted 
viral particles isolated from Huh7.5 transfected with Luciferase-Jc1 RNA and treated with 
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the DGAT1 inhibitor (20 μM) or DMSO. Shown are luciferase values expressed as percent 
of DMSO control (mean ± s.d.; n = 3; **p < 0.01). (h) Representative images and 
quantification of epifluorescence of Huh7 Lunet cells electroporated with eGFP-Jc1 RNA 
and treated with DMSO or DGAT1 inhibitor (20 μM) after oil-red-O (ORO) staining. LD 
area: mean of 1000 cells ± s.e.m.; LD diameter: mean of > 1600 LDs ± s.e.m.; LD number: 
mean of > 50 cells ± s.e.m. (i) Western blot analysis of cell extracts or isolated LD fractions 
from cells described in h). TG: extracted triglycerides analyzed by thin layer 
chromatography. (j) Indirect immunofluorescence of double-stranded RNA (α-dsRNA) at 
LDs (ORO) in cells described in h) (scale bar = 10 μm) and quantification of overlap of the 
signals for double-stranded RNAs and ORO per cell (mean of 30 cells ± s.e.m.).
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Fig. 2. Specific interaction of the HCV core protein with DGAT1
(a) Coimmunoprecipitation assays in 293T cells transfected with expression vectors for the 
HCV core protein and Flag-DGAT1 or Flag-DGAT2 proteins and treated with DGAT1 
inhibitor (20 μM) or DMSO. After immunoprecipitation with α-Flag agarose, the core 
protein was detected by western blotting with α-core antibodies. (b) Coimmunoprecipitation 
of the HCV core protein with endogenous DGAT1 in Huh7 hepatoma cells transduced with 
a core-expressing lentiviral vector. (c) Coimmunoprecipitation of the HCV core protein with 
endogenous DGAT1 in Huh7.5 and Huh7 Lunet cells electroporated with eGFP-Jc1 RNA. 
(d) Indirect immunofluorescence of core and endogenous DGAT1 in Huh7 cells transfected 
with wild-type or mutant (SPMT) core expression vectors (scale bar = 10 μm). (e) 
Coimmunoprecipitation assays in 293T cells transfected with expression vectors for wild-
type (WT), mutant (SPMT) or truncated (1–173) core protein and the Flag-DGAT1-
expressing plasmid. Arrows mark unprocessed (upper) and processed (lower) core protein. 
(f) Model of HCV core recruitment to DGAT1-generated LDs. See text for details.
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